Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient.
J Infect Chemother
; 23(11): 774-777, 2017 Nov.
Article
em En
| MEDLINE
| ID: mdl-28527652
ABSTRACT
Nivolumab, a new immune checkpoint inhibitor, binds to programmed cell death-protein 1 receptors on T cell, blockades binding of its ligands, and augments the immunologic reaction against tumor cells. Augmented immune response, however, may lead to immune-related adverse events. Herein we describe a rare case of bilateral anterior uveitis induced by nivolumab treatment for metastatic melanoma. A 54-year-old woman presented with mild conjunctival redness and blurred vision two months after initiating nivolumab treatment. Ophthalmological examination revealed bilateral non-granulomatous anterior uveitis. The flare values in the anterior chamber were monitored as an objective inflammatory index during nivolumab therapy and clinical time course was reported in this paper.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Uveíte
/
Tolerância a Antígenos Próprios
/
Receptor de Morte Celular Programada 1
/
Melanoma
/
Anticorpos Monoclonais
/
Antineoplásicos
Limite:
Female
/
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article